BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/22/2022 8:29:42 AM | Browse: 461 | Download: 842
 |
Received |
|
2022-01-31 19:35 |
|
Peer-Review Started |
|
2022-01-31 19:36 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-13 02:00 |
|
Revised |
|
2022-04-27 12:44 |
|
Second Decision |
|
2022-05-24 03:18 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-28 07:17 |
|
Articles in Press |
|
2022-05-28 07:17 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-06-01 06:05 |
|
Publish the Manuscript Online |
|
2022-06-22 08:29 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kathrine S Rallis, Dimitrios Makrakis, Ioannis A Ziogas and Georgios Tsoulfas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Georgios Tsoulfas, FACS, FICS, MD, PhD, Professor, Department of Transplantation Surgery, Aristotle University School of Medicine, 66 Tsimiski Street, Thessaloniki 54622, Greece. tsoulfasg@gmail.com |
| Key Words |
Hepatocellular carcinoma; Liver cancer; Immunotherapy; Immune checkpoint inhibitors; Clinical trials; Real-world data |
| Core Tip |
In the last five years, immune checkpoint inhibitors (ICIs) have entered the treatment landscape of hepatocellular carcinoma (HCC) in the 1st and 2nd line setting. However, due to restrictions in clinical trial inclusion and exclusion criteria, there remains a need for further real-world data on the efficacy, toxicity, and cost-effectiveness of ICIs in a broader cohort of HCC patients. New trials are underway investigating further ICI regimens, including combination therapy strategies, while novel immunotherapies are also being brought to the fore. This review discusses key clinical trials, real-world data, and future advances of immunotherapy for HCC, with a focus on ICIs. |
| Publish Date |
2022-06-22 08:29 |
| Citation |
Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i6/448.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i6.448 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
